gtg up another 8..45% on nasdaq, page-8

http://www.americanbankingnews.com/2011/01/18/genetic-technologies-nasdaq-gene-hits-new-52-week-high-at-3-43/


Shares of Genetic Technologies (NASDAQ: GENE) hit a new 52-week high on Tuesday. The stock traded as high as $3.43 during mid-day trading and last traded at $3.14. The stock previously closed at $2.90.

Genetic Technologies Limited is engaged in a diagnostic product business. The Company translates genetic tests into products and services. The Company’s cancer diagnostics business focused on building a sustainable stable of products and services. The Company operates in three divisions: genetic testing, including cancer diagnostics; licensing, and research. BREVAGen provides a personalized genetics based risk score for such women, so guiding preventive therapy or advanced monitoring decisions. The majority of its customers are clinicians. The Company’s five overseas subsidiaries include Gtech International Resources Limited, Genetic Technologies (Beijing) Limited, GeneType AG, GeneType Corporation and Phenogen Sciences Inc. In April 2010, Genetic Technologies acquired the assets of Perlegen Sciences Inc., which included non-familial breast cancer risk assessment test BREVAGen.

Genetic Technologies (NASDAQ: GENE) traded up 17.33% during mid-day trading on Tuesday. The stock has a 52 week low of $0.65 and a 52 week high of $3.43. Its 50-day moving average is $1.19 and its 200-day moving average is $0.93. The company has a market cap of $49.8 million and a price-to-earnings ratio of N/A.